Eli Lilly Commits £279 Million to UK Life Sciences Sector in Groundbreaking Partnership

Investment Amount:
Eli Lilly, the world's largest pharmaceutical company, has committed £279 million to the UK life sciences sector as part of a new government partnership.

Lilly Gateway Labs:
The investment will fund the launch of the first 'Lilly Gateway Labs' innovation accelerator in Europe, providing lab space, mentorship, and potential financial backing to early-stage life sciences businesses.

Focus on Obesity:
The collaboration aims to tackle obesity, which is the second biggest preventable cause of cancer and costs the NHS over £11 billion a year.

Partnership Goals:
The partnership seeks to combine the UK's leading scientific minds with the National Health Service to accelerate the delivery of future medicines and improve long-term health outcomes for those living with obesity.

Economic Impact:
The investment is expected to boost the UK's life sciences sector, which already supports 300,000 jobs nationwide and drove £800 million in foreign direct investment into the UK in 2023.

Government Support:
The partnership was announced at the International Investment Summit and is seen as a demonstration of the UK's commitment to being "open for business" and a world leader in life sciences.